ArticleTherapeutic advances in medical oncology2025

TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer.

Heather L McArthur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.